Literature DB >> 26405027

Caspase-1 is required for maintenance of marginal zone B cells in pristane-induced lupus.

M D Morse1, K L Clark1, M Cascalho2, J M Kahlenberg3.   

Abstract

OBJECTIVE: Caspase-1 is required for nephritis and robust autoantibody development in the pristane model of murine lupus. The objective of this study was to evaluate the immune response and to study the splenic B and T cell populations in wild-type (WT) and caspase-1-/- mice following pristane injection in order to develop an understanding of why absence of caspase-1 is protective in pristane-induced lupus.
METHODS: Immunization responses to NP-Ficoll and NP-ovalbumin were assessed in WT and caspase-1-/- mice. In vitro IgM and IgG responses to R848 were measured by ELISA. Serum IgM anti-dsDNA and IL-1β were also measured by ELISA. B and T cell populations 2 weeks and 6 months following pristane injection were measured by flow cytometry in WT and caspase-1-/- mice.
RESULTS: Caspase-1-/- mice generate equivalent IgG responses to NP-Ficoll and NP-ova antigens when compared to wild-type mice. Additionally, they secrete IgM and IgG in response to TLR7 activation. Pristane injected WT and caspase-1-/- mice generate robust IgM anti-dsDNA responses. Caspase-1-/- mice have a significant reduction in marginal zone B cell populations compared to WT 6 months after pristane exposure whereas T cell responses are intact in these mice.
CONCLUSIONS: Caspase-1-/- mice have intact immune responses but do not develop an expanded marginal zone B cell population in response to pristane-induced lupus. This may be one explanation for reduced IgG autoantibody production in these mice.
© The Author(s) 2015.

Entities:  

Keywords:  B-cell; Caspase-1; autoantibody; lupus

Mesh:

Substances:

Year:  2015        PMID: 26405027      PMCID: PMC4679614          DOI: 10.1177/0961203315606982

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  16 in total

1.  The inflammatory cytokine IL-18 induces self-reactive innate antibody responses regulated by natural killer T cells.

Authors:  Sara Lind Enoksson; Emilie K Grasset; Thomas Hägglöf; Nina Mattsson; Ylva Kaiser; Susanne Gabrielsson; Tracy L McGaha; Annika Scheynius; Mikael C I Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-01       Impact factor: 11.205

2.  P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway.

Authors:  Jijun Zhao; Hongyue Wang; Chao Dai; Hongyang Wang; Hui Zhang; Yuefang Huang; Shuang Wang; Felicia Gaskin; Niansheng Yang; Shu Man Fu
Journal:  Arthritis Rheum       Date:  2013-12

3.  TLR agonists promote marginal zone B cell activation and facilitate T-dependent IgM responses.

Authors:  Anatoly V Rubtsov; Cristina L Swanson; Scott Troy; Pamela Strauch; Roberta Pelanda; Raul M Torres
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

4.  Monocytes from Irf5-/- mice have an intrinsic defect in their response to pristane-induced lupus.

Authors:  Lisong Yang; Di Feng; Xiaohui Bi; Rivka C Stone; Betsy J Barnes
Journal:  J Immunol       Date:  2012-08-29       Impact factor: 5.422

Review 5.  Inflammasomes and their roles in health and disease.

Authors:  Mohamed Lamkanfi; Vishva M Dixit
Journal:  Annu Rev Cell Dev Biol       Date:  2012-09-10       Impact factor: 13.827

6.  Mechanisms of tumor necrosis factor α antagonist-induced lupus in a murine model.

Authors:  Yuan Xu; Haoyang Zhuang; Shuhong Han; Chao Liu; Hai Wang; Clayton E Mathews; John Massini; Lijun Yang; Westley H Reeves
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

Review 7.  Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes.

Authors:  Andrea Cerutti; Montserrat Cols; Irene Puga
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106

8.  Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-κB activation.

Authors:  Jijun Zhao; Hui Zhang; Yuefang Huang; Hongyue Wang; Shuang Wang; Chunmei Zhao; Yingjie Liang; Niansheng Yang
Journal:  Int Immunopharmacol       Date:  2013-06-12       Impact factor: 4.932

9.  Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus.

Authors:  Pui Y Lee; Yi Li; Hanno B Richards; Fay S Chan; Haoyang Zhuang; Sonali Narain; Edward J Butfiloski; Eric S Sobel; Westley H Reeves; Mark S Segal
Journal:  Arthritis Rheum       Date:  2007-11

10.  TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus.

Authors:  Pui Y Lee; Yutaro Kumagai; Yi Li; Osamu Takeuchi; Hideo Yoshida; Jason Weinstein; Erinn S Kellner; Dina Nacionales; Tolga Barker; Kindra Kelly-Scumpia; Nico van Rooijen; Himanshu Kumar; Taro Kawai; Minoru Satoh; Shizuo Akira; Westley H Reeves
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Pristane-induced lupus: considerations on this experimental model.

Authors:  Eduarda Correa Freitas; Mayara Souza de Oliveira; Odirlei André Monticielo
Journal:  Clin Rheumatol       Date:  2017-09-06       Impact factor: 2.980

Review 2.  Purinergic signalling in autoimmunity: A role for the P2X7R in systemic lupus erythematosus?

Authors:  Francesco Di Virgilio; Anna Lisa Giuliani
Journal:  Biomed J       Date:  2016-10-27       Impact factor: 4.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.